Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agendia names new CFO
Most recently, Mr Schmidt was a principal at a consulting firm he founded in 2002, providing high-level interim financial management and M&A services. Prior to that, Mr Schmidt
Most recently, Mr Schmidt was a principal at a consulting firm he founded in 2002, providing high-level interim financial management and M&A services. Prior to that, Mr Schmidt
In connection with this abbreviated new drug application, Impax provided notice that its submission includes a paragraph IV certification stating the company believes its product does not infringe
According to the company, this novel vaccine platform enables presentation of multiple carbohydrate antigens on a single synthetic scaffold and has been shown to trigger an in vivo
ALTU-238 is being developed as a subcutaneously administered, long acting formulation of recombinant human growth hormone that employs Altus’s proprietary protein crystallization and formulation technology, for patients with
In this new position, Dr Skowronski will be responsible for development and execution of clinical protocols and providing medical input and review of clinical development strategy. Prior to
Mr Hanlon was previously vice president of R&D for Boston Scientific’s neurovascular division, where he oversaw a 100-person multi-disciplinary department and numerous successful product launches. Prior to Boston
Prior to her appointment as president and CEO, Ms Popovits served as president and COO since joining Genomic Health in February 2002, and as a director since March
An additional $12 million of BioThrax revenue originally planned for the fourth quarter of 2008 is projected to be recognized in 1Q 2009. This additional revenue is attributable
The $25 million upfront payment to Depomed under the agreement is due 60 days following completion of the Hart-Scott-Rodino Antitrust Improvements Act (HSR) review. Under the terms of
An additional approximately $267 million, or $3 per Indevus share, in cash will be payable in the future upon achievement of certain regulatory and sales milestones. The transaction